Table 2.
Overview of the number of studies and the countries that identified determinants associated with vaccine acceptance.
| Determinants | Total Studies (n) | Country * | Reviews/Reports/Multi-National Studies |
|---|---|---|---|
| Age | |||
| 18–30 | 5 | China, Egypt, Italy, Palestine [14,15,18,31,37] | |
| 30–50 | 24 | China, Cyprus, Czech Republic, France, Germany, Greece, India, Saudi Arabia, Spain, Turkey, UK, US [12,13,16,19,21,26,27,38,47,48,50,51,54,58,59,60,62] | Biswas et al., Hajure et al., Khubchandani et al., Leigh et al., Li et al., Luo et al., PAHO [8,25,29,32,34,35,64] |
| >60 | 4 | Azerbaijan, Germany, Switzerland, UK [10,17,43,63] | |
| Gender | |||
| Male | 25 | Albania, Cyprus, Czech Republic, Egypt, France, Germany, Greece, Kosovo, Lebanon, Palestine, Spain, Switzerland, Turkey, UAE, UK, US [10,16,18,21,23,24,26,36,37,38,42,43,44,46,49,52,54,59,61,63] | Biswas et al., Hajure et al., Khubchandani et al., Li et al., Luo et al. [8,25,29,34,35] |
| Female | 3 | Cyprus, Greece, Saudi Arabia [13,19,22] | |
| Education | 12 | China, Germany, Greece, Italy, Turkey, US [20,23,27,43,46,55,60] | Biswas et al., Hajure et al., Khubchandani et al., Li et al., Shakeel et al. [8,25,29,34,53] |
| Occupation | |||
| Nurses | 18 | China, Egypt, France, Germany, Greece, India, Israel, Italy, Palestine, Switzerland, Turkey, UK, US [10,12,14,16,18,21,27,36,37,46,48,50,59,60,62,63] | Li et al., PAHO [34,64] |
| Physicians | 31 | China, Cyprus, Czech Republic, Egypt, France, Germany, Greece, India, Israel, Italy, Palestine, Slovakia, Spain, Switzerland, Turkey, UK, US [10,12,14,15,16,18,20,21,23,26,27,36,37,38,40,46,47,48,50,51,54,56,57,60,62,63] | Biswas et al., Hajure et al., Leigh et al., Li et al., PAHO [8,25,32,34,64] |
| Ethnicity | 5 | UK, US [10,23,59] | Hajure et al., Li et al. [25,34] |
| Comorbidities | 9 | Azerbaijan, China, Egypt, Greece, US [17,18,23,36,57] | Biswas et al., Hajure et al., Khubchandani et al., Li et al., [8,25,29,34] |
| Previous Influenza Vaccination | 39 | Albania, Azerbaijan, China, Cyprus, Czech Republic, Egypt, France, Greece, Italy, Kosovo, Lebanon, Palestine, Slovakia, Spain, Switzerland, Tunisia, Turkey, UAE, UK, US [10,14,15,16,17,18,19,21,22,23,24,26,27,28,36,37,38,40,41,44,45,47,48,49,52,54,55,56,57,59,60,61,63] | Biswas et al., Hajure et al., Khubchandani et al., Li et al., Luo et al., Shakeel et al. [8,25,29,34,35,53] |
| Previous COVID-19 Infection | 16 | Azerbaijan, Albania, Cyprus, Czech Republic, Egypt, France, Greece, Italy, Kosovo, Lebanon, Turkey, Slovakia, Spain, UK, US [16,17,18,27,40,44,47,48,49,54,56,58,61] | Biswas et al., Hajure et al., Li et al. [8,25,34] |
* Cross-sectional and cohort studies are categorized here according to the determinants that they found were associated with vaccine acceptance and the countries in which the study was conducted.